MEDITE Cancer Diagnostics
MEDITE® Group is a medical technology company specializing in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases.
MEDITE is poised to become a disruptive force from rapid revenue and market share growth resulting from the introduction of major innovative products in the multibillion dollar global histology and cytology cancer detection marketplace.
Investor relations provided by KCSA Strategic Communications.
Recent News & Press Releases
November 15, 2017
MEDITE Cancer Diagnostics Reports Appointments of New Chairman of the Board and Chief Executive Officer
November 8, 2017
MEDITE Cancer Diagnostics Reports Closing of $5.4 Million Private Financing, Providing Working Capital to Drive Commercial Plan Execution
October 3, 2017
May 10, 2017